Xenon Pharmaceuticals (XENE) Research & Development (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Research & Development data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, Research & Development rose 22.66% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was -$116.9 million, a 204.78% decrease from a year earlier, with the FY2025 full-year figure at $12.5 million, up 11.46% from the prior year.
• Research & Development for Q1 2026 stood at $4.2 million, up from -$200.7 million in the prior quarter.
• Over the last five years, Research & Development for XENE reached as high as $77.1 million in Q3 2025 and fell as low as -$200.7 million in Q4 2025.
• Historically, Research & Development has averaged $12.6 million across 5 years, with a median of $29.4 million in 2022.
• Across the five-year window, Research & Development jumped 164.52% in 2023 and plunged 14019.56% in 2025, its largest moves.
• Year by year, Research & Development stood at -$63.7 million in 2022, then soared by 164.52% to $41.1 million in 2023, then slumped by 96.49% to $1.4 million in 2024, then plunged by 14019.56% to -$200.7 million in 2025, then surged by 102.09% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $4.2 million in Q1 2026, -$200.7 million in Q4 2025, and $77.1 million in Q3 2025.